Jeff Martin
Stock Analyst at Roth Capital
(4.34)
# 386
Out of 5,127 analysts
65
Total ratings
59.02%
Success rate
16.21%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BWMN Bowman Consulting Group | Maintains: Buy | $45 → $50 | $34.77 | +43.80% | 6 | Dec 9, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $280 → $292 | $279.61 | +4.43% | 17 | Dec 1, 2025 | |
| PERI Perion Network | Reiterates: Buy | $14 → $15 | $9.39 | +54.42% | 10 | Nov 13, 2025 | |
| NSP Insperity | Maintains: Buy | $85 → $74 | $43.84 | +68.80% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $17.91 | +50.75% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $3.81 | +31.23% | 1 | May 14, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $5.11 | +76.13% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $37.83 | +18.95% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $20.28 | +47.93% | 6 | Nov 5, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $0.85 | +677,626.79% | 2 | Nov 15, 2017 |
Bowman Consulting Group
Dec 9, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $34.77
Upside: +43.80%
OSI Systems
Dec 1, 2025
Maintains: Buy
Price Target: $280 → $292
Current: $279.61
Upside: +4.43%
Perion Network
Nov 13, 2025
Reiterates: Buy
Price Target: $14 → $15
Current: $9.39
Upside: +54.42%
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $43.84
Upside: +68.80%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $17.91
Upside: +50.75%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $3.81
Upside: +31.23%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $5.11
Upside: +76.13%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $37.83
Upside: +18.95%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $20.28
Upside: +47.93%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $0.85
Upside: +677,626.79%